Emerging Short-Acting Insulin Market Trends: Innovative Wearable Insulin Pod Gains FDA Clearance For Type 2 Diabetes Shaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Short-Acting Insulin Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been consistent growth in the short-acting insulin market size. The market is projected to expand from $11 billion in 2024 to $11.54 billion in 2025, registering a compound annual growth rate (CAGR) of 4.8%. The observed growth in the historical period is due to several factors including an upsurge in the population suffering from type 1 diabetes, growing elderly population, increase in funding for research and development, rise in the number of diagnosed cases, and the effect of escalating urbanization.

How Will the Short-Acting Insulin Market Size Evolve and Grow by 2029?
In the coming years, the market size of short-acting insulin is anticipated to witness robust growth, expanding to "$14.14 billion by 2029 with a compound annual growth rate (CAGR) of 5.2%. This anticipated growth during the forecast period is due to factors such as increased governmental initiatives, more support from the government, advancements in production technology, greater acceptance of insulin therapy, and the emergence of personalized healthcare. Key trends for the forecast period are the improvements in insulin delivery devices and technology, the introduction of innovative quick-acting insulin analogs, the creation of biosimilars, a shift towards patient-focused care, and progress in formulation.

View the full report here:
https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

What Drivers Are Propelling the Growth of Short-Acting Insulin Market Forward?
The rise in instances of type 1 diabetes is anticipated to bolster the expansion of the short-acting insulin market. Type 1 diabetes, characterized as an autoimmune disorder where the body obliterates cells that produce insulin, necessitates a lifetime of insulin treatment. A combination of genetic and environmental factors as well as a surge in autoimmune disorders contribute to the increasing occurrence of Type 1 diabetes. Short-acting insulin allows for the effective management of type 1 diabetes through rapid blood sugar control, mirroring the natural insulin response. For example, Diabetes Australia, an organization devoted to increasing diabetes awareness, reported that around 134,000 Australians were living with Type 1 diabetes in 2022, a number which climbed to 135,423 in 2023. Consequently, the rising occurrence of type 1 diabetes is stimulating the growth of the short-acting insulin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

What Long-Term Trends Will Define the Future of the Short-Acting Insulin Market?
Key players in the short-acting insulin market are shifting their focus towards innovative goods like insulin pods. These pods are tubeless, wearable systems that provide ongoing insulin infusion for those struggling with diabetes. For instance, in April 2023, the American medical device firm Insulet Corporation reported that the U.S. Food and Drug Administration (FDA) had given clearance for their product Omnipod GO. This revolutionary insulin pod that only delivers basal insulin has been specifically designed for type 2 diabetes in adults. It provides a constant delivery of insulin, without the need for another controlling device. The Omnipod GO simplifies the treatment of diabetes by removing the necessity for daily injections and providing preset insulin rates. It increases convenience for both patients and healthcare providers through its easy-to-use design and availability at pharmacies. This product launch underscores Insulet's commitment to enhancing diabetes treatment through cutting-edge technology.

What Are the Key Segments in the Short-Acting Insulin Market?
The short-acting insulin market covered in this report is segmented -

1) By Formulation: Regular Insulin, Rapid-Acting Insulin
2) By Dosage Form: Vials, Pre-filled Pens, Cartridges
3) By Route Of Administration: Subcutaneous, Intravenous
4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes
5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:
1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin
2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Who Are the Key Players Shaping the Short-Acting Insulin Market's Competitive Landscape?
Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

What Geographic Markets Are Powering Growth in the Short-Acting Insulin Market?
North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21287

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.